Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2018-04-24 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of a dividend distribution plan approved at the 2017 Annual General Meeting. It details the dividend amount per share, the record date, the ex-dividend date, the shareholders entitled to the dividend, and the method of dividend payment. It references the shareholder meeting resolution and the dividend payment specifics but does not contain financial statements or comprehensive financial data. The document is short (2199 characters) and serves as a formal notice of dividend distribution rather than a full financial report or earnings release. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2018-04-24 Chinese
第七届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing SL Pharmaceutical Co., Ltd. It includes approval of the 2018 Q1 report text and full report, amendments to the Articles of Association, internal management system revisions, and new risk investment management system proposals. The document is short (1675 characters) and primarily announces the passing of resolutions and approvals rather than containing the full financial report or detailed financial data. It references the full quarterly report being available elsewhere (on the company website and in a newspaper). Therefore, this document is an announcement of meeting resolutions and approvals, not the actual quarterly report itself. It fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than an Interim/Quarterly Report (IR) or other specific report type.
2018-04-24 Chinese
募集资金使用管理制度（2018年4月）
Capital/Financing Update Classification · 95% confidence The document is titled as a management system for the use of raised funds by Beijing SL Pharmaceutical Co., Ltd. It details the rules, procedures, and oversight mechanisms for the management and use of funds raised through securities issuance. The content includes regulatory references, internal controls, reporting obligations, and supervisory responsibilities related to fundraising activities. There is no indication that this is an actual financial report, audit report, or announcement of voting results. Instead, it is a detailed policy or governance document about capital raising and fund usage management. This fits best under Capital/Financing Update (CAP) as it relates to fundraising management and use of proceeds.
2018-04-24 Chinese
重大信息内部报告制度（2018年4月）
Governance Information Classification · 95% confidence The document is titled as an internal reporting system for material information of Beijing SL Pharmaceutical Co., Ltd. It outlines procedures and responsibilities for reporting significant company information internally, including definitions of what constitutes material information, reporting obligations, and confidentiality requirements. There are references to regulatory laws and stock exchange rules, but the document itself is a policy or procedural document rather than a financial report, announcement, or regulatory filing. It does not contain financial data, earnings, voting results, or any specific event announcement. It is a governance-related document detailing internal rules and processes for information disclosure. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4545 characters, which is substantial and contains detailed governance content rather than a brief announcement or certification.
2018-04-24 Chinese
第七届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's seventh board of directors' second meeting, including approval of the 2018 first quarter report, amendments to the company charter, internal management system revisions, and plans for a shareholders' meeting. It contains voting results and detailed governance-related content such as changes to company bylaws and internal rules. There is no full financial report or comprehensive financial data presented, but rather decisions and governance matters. The document is not a full quarterly or annual report, nor is it a simple announcement of a report publication. It is primarily about board meeting resolutions and governance changes. Therefore, the document fits best under Board/Management Information (MANG).
2018-04-24 Chinese
公司章程（2018年4月）
Governance Information Classification · 95% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Beijing SL Pharmaceutical Co., Ltd., dated April 2018. It contains detailed provisions about the company's organization, shareholder rights, board of directors, management, share issuance, shareholder meetings, voting procedures, and other governance matters. It is a comprehensive governance document that sets out the internal rules and structure of the company rather than a financial report, meeting presentation, or announcement. There is no indication that this is an annual report, earnings release, proxy statement, or any other type of financial or regulatory filing. The content aligns with the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2018-04-24 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.